CMC

精繕生物目前已有自己的GMP車間支持不同來源的NK細胞的工藝開發和生產。公司的最終目標是開發“現貨型”的細胞治療產品用于血液瘤和實體瘤。NK細胞的開發和生產過程非常復雜，涉及到不同的技術，其中包括基因編輯，應用PiggyBac轉座子進行基因遞送，體外細胞分化和成熟。我們計劃在2023年底，建成新的研發和生產基地，位于上海張江，面積約4000平米。建成后將有效支持我們的NK項目的管線開發，擴大細胞的GMP生產能力。

Our aim is to develop off-the-shelf immunotherapy product against blood and solid tumors. The production of NK cells involves sophisticated steps, including gene editing, gene delivery by PiggyBac transposase and cell differentiation and maturation.

By the end of 2023, we will enter a new facility, a 4000-square-meter complex, located at Shanghai Zhangjiang district. The facility will support our iPSC-derived NK R&D and, more importantly, expand our manufacture capacity.